BR112014027561A2 - moduladores alostéricos dos receptor acetilcolina alfa 7 nicotínicos, seus derivados e respectivas utilizações - Google Patents
moduladores alostéricos dos receptor acetilcolina alfa 7 nicotínicos, seus derivados e respectivas utilizaçõesInfo
- Publication number
- BR112014027561A2 BR112014027561A2 BR112014027561A BR112014027561A BR112014027561A2 BR 112014027561 A2 BR112014027561 A2 BR 112014027561A2 BR 112014027561 A BR112014027561 A BR 112014027561A BR 112014027561 A BR112014027561 A BR 112014027561A BR 112014027561 A2 BR112014027561 A2 BR 112014027561A2
- Authority
- BR
- Brazil
- Prior art keywords
- derivatives
- acetylcholine receptor
- allosteric modulators
- receptor allosteric
- nicotinic alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644318P | 2012-05-08 | 2012-05-08 | |
| US201261644411P | 2012-05-08 | 2012-05-08 | |
| US201261645935P | 2012-05-11 | 2012-05-11 | |
| US201361801544P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/040117 WO2013169889A1 (en) | 2012-05-08 | 2013-05-08 | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014027561A2 true BR112014027561A2 (pt) | 2017-06-27 |
Family
ID=48430966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014027561A BR112014027561A2 (pt) | 2012-05-08 | 2013-05-08 | moduladores alostéricos dos receptor acetilcolina alfa 7 nicotínicos, seus derivados e respectivas utilizações |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150099758A1 (pt) |
| EP (1) | EP2846803B1 (pt) |
| JP (1) | JP2015516429A (pt) |
| KR (1) | KR20150008891A (pt) |
| CN (1) | CN104334175A (pt) |
| AU (1) | AU2013259565A1 (pt) |
| BR (1) | BR112014027561A2 (pt) |
| CA (1) | CA2871651A1 (pt) |
| EA (1) | EA201491857A1 (pt) |
| HK (1) | HK1208154A1 (pt) |
| IN (1) | IN2014MN02121A (pt) |
| MX (1) | MX2014013499A (pt) |
| SG (1) | SG11201406914XA (pt) |
| WO (1) | WO2013169889A1 (pt) |
| ZA (1) | ZA201408847B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2977375A1 (en) * | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| EP3172204A1 (en) * | 2014-07-25 | 2017-05-31 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| EP2977377A1 (en) * | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| EP2977376A1 (en) * | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| CN107398300B (zh) * | 2017-07-24 | 2020-08-21 | 中国科学院化学研究所 | 芳香族酰胺芳环c-h键直接氨基化反应的方法 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| JP2023509260A (ja) | 2019-08-14 | 2023-03-08 | インサイト・コーポレイション | Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物 |
| AR120184A1 (es) | 2019-10-11 | 2022-02-02 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| WO2022096990A1 (en) * | 2020-11-05 | 2022-05-12 | Cadila Healthcare Limited | Novel hetrocyclic compounds |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| NZ522217A (en) * | 2000-04-28 | 2004-04-30 | Tanabe Seiyaku Co | Cyclic compounds |
| US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| WO2006071184A1 (en) * | 2004-12-28 | 2006-07-06 | Astrazeneca Ab | Aryl sulphonamide modulators |
| PL2354126T3 (pl) * | 2005-01-14 | 2014-03-31 | Chemocentryx Inc | Sulfonamidy heteroarylowe i CCR2 |
| US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| MX2010011358A (es) * | 2008-04-17 | 2010-11-10 | Glaxo Group Ltd | Indoles como moduladores del receptor nicotinico de acetilcolina subtipo alfa-71. |
| KR20120087936A (ko) * | 2009-10-06 | 2012-08-07 | 선에시스 파마슈티컬스 인코포레이티드 | Ｐｄｋ１ 저해제로서 유용한 헤테로시클릭 화합물 |
| GB201106829D0 (en) * | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
-
2013
- 2013-05-08 JP JP2015511659A patent/JP2015516429A/ja active Pending
- 2013-05-08 SG SG11201406914XA patent/SG11201406914XA/en unknown
- 2013-05-08 EA EA201491857A patent/EA201491857A1/ru unknown
- 2013-05-08 WO PCT/US2013/040117 patent/WO2013169889A1/en active Application Filing
- 2013-05-08 KR KR20147033675A patent/KR20150008891A/ko not_active Application Discontinuation
- 2013-05-08 CA CA2871651A patent/CA2871651A1/en not_active Abandoned
- 2013-05-08 IN IN2121MUN2014 patent/IN2014MN02121A/en unknown
- 2013-05-08 AU AU2013259565A patent/AU2013259565A1/en not_active Abandoned
- 2013-05-08 BR BR112014027561A patent/BR112014027561A2/pt not_active IP Right Cessation
- 2013-05-08 CN CN201380029104.9A patent/CN104334175A/zh active Pending
- 2013-05-08 US US14/398,968 patent/US20150099758A1/en not_active Abandoned
- 2013-05-08 EP EP13722661.9A patent/EP2846803B1/en not_active Not-in-force
- 2013-05-08 MX MX2014013499A patent/MX2014013499A/es unknown
-
2014
- 2014-12-03 ZA ZA2014/08847A patent/ZA201408847B/en unknown
-
2015
- 2015-09-09 HK HK15108755.1A patent/HK1208154A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2846803B1 (en) | 2017-06-21 |
| JP2015516429A (ja) | 2015-06-11 |
| CN104334175A (zh) | 2015-02-04 |
| MX2014013499A (es) | 2015-11-13 |
| CA2871651A1 (en) | 2013-11-14 |
| US20150099758A1 (en) | 2015-04-09 |
| AU2013259565A1 (en) | 2014-11-13 |
| SG11201406914XA (en) | 2014-11-27 |
| HK1208154A1 (en) | 2016-02-26 |
| IN2014MN02121A (pt) | 2015-09-04 |
| KR20150008891A (ko) | 2015-01-23 |
| WO2013169889A1 (en) | 2013-11-14 |
| EA201491857A1 (ru) | 2015-04-30 |
| ZA201408847B (en) | 2015-12-23 |
| EP2846803A1 (en) | 2015-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014027561A2 (pt) | moduladores alostéricos dos receptor acetilcolina alfa 7 nicotínicos, seus derivados e respectivas utilizações | |
| CY2018022I1 (el) | Πολυκυκλικες ενωσεις καρβαμοϋλπυριδονης και φαρμακευτικη χρηση αυτων | |
| BR302012003594S1 (pt) | "configuração aplicada em fraco" | |
| BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
| DK3042785T3 (da) | Panel med coating og direkte tryk | |
| BR112014028359A2 (pt) | absorvente com múltiplas zonas gráficas | |
| DK2900645T3 (da) | Herbicidt aktive 3-phenylisoxazolinderivater | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| BR112014000049A2 (pt) | pirrolotriazinas substituídas com hidroximelilarilo e sua utilização | |
| BR112014032488A2 (pt) | embalagem, e blanqueta | |
| DK2917181T3 (da) | Heteroarylderivater og anvendelser deraf | |
| BR112013022000A2 (pt) | dispositivo de gaveta e dispositivo de transação de meio | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| DK2745849T3 (da) | Polydeoxyribonukleotidsammensætning og anvendelser deraf | |
| BR302013002263S1 (pt) | Configuração aplicada em fechamento | |
| EP2670731A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINE ACETYLCHOLIN RECEPTOR ALPHA 7 AND USES THEREOF | |
| BR112015010797A2 (pt) | compostos aniônicos substituídos, e, composição farmacêutica | |
| BR112015010271A2 (pt) | produto de comicronização, composição farmacêutica e seus usos | |
| BR112015002979A2 (pt) | forma cristalina, e, composição farmacêutica | |
| BR112015002646A2 (pt) | composto e composição farmacêutica | |
| BR302012003846S1 (pt) | Configuração aplicada em almofada | |
| BR302013000912S1 (pt) | Configuração aplicada em fechamento | |
| BR112015003217A2 (pt) | novos derivados de piridina. | |
| BR302012004867S1 (pt) | Configuração aplicada em instrumento de escrita | |
| BR302012003979S1 (pt) | Configuração aplicada em fármaco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B06I | Technical and formal requirements: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |